HEMATOLOGICAL DISEASES AND COVID-19 (Atena Editora)

Abstract

Hematologic neoplasms are a heterogeneous group of cancers comprising several subgroups of neoplasms. So far, despite major epidemiological concerns about quality of care, limited data are available for patients with hematologic malignancies. To retrospectively analyze the epidemiological, clinical and hematological characteristics of patients at the Hospital Universitário de Vassouras, Rio de Janeiro, Brazil during the COVID-19 pandemic. In addition, it aims to report the most prevalent hematological diseases in the municipality. In addition, it is important to consider that patients with hematological malignancy are immunocompromised. It is expected that the present study will reveal that there is an increased risk of serious events related to COVID-19 (ICU admission, need for MV or death) in patients with hematologic malignancy compared to patients infected with COVID-19 without cancer. due to the high vulnerability of patients with hematological malignancies in the current pandemic. It was observed that there is an increased risk of serious events related to COVID-19 (ICU admission, need for MV or death) in patients with hematologic malignancy compared to patients infected with COVID-19 without cancer due to the high vulnerability of the patients. patients with hematologic malignancies in the current pandemic. It was therefore noted that clinicians must pay close attention to treating COVID-19 patients with hematologic malignancy. Telephone screening or other online technologies must be used to verify the need for treatment or follow-up at inpatient or outpatient clinics. In non-life-threatening patients, hospitalization must be postponed. Patients with fever or other symptoms that may be related to COVID-19 must be tested for SARS-CoV-2 RNA and they must not be accepted into the hematology ward before the possibility of COVID-19 has been ruled out.